- Conditions
- Safety and Pharmacokinetics in Healthy Volunteer Subjects
- Interventions
- CC-223
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1705–1728
of 29,139
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- E7070 + irinotecan combination, Irinotecan + E7070 combination
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Standard adjuvant chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more
- Conditions
- Urea Cycle Disorders
- Interventions
- HPN-100, BUPHENYL®
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Houston, Texas
- Conditions
- RSV Infection, QTc Interval
- Interventions
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas
- Conditions
- Advanced Solid Tumor
- Interventions
- QTX3046, Cetuximab
- Drug · Combination Product
- Lead sponsor
- Quanta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • Durham, North Carolina • Houston, Texas + 2 more
- Conditions
- Healthy
- Interventions
- Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Interventions
- Tirzepatide, Acetaminophen, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban, Warfarin, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Leukemia, Lymphocytic, Acute
- Interventions
- Methotrexate, Vincristine, PEG-l-asparaginase, Dexamethasone, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
- Interventions
- HY209GEL Active, Placebo
- Drug · Other
- Lead sponsor
- Shaperon
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Encino, California • Los Angeles, California + 4 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Omega 3 Fatty Acids, Corn oil
- Drug · Dietary Supplement
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Melanoma, Advanced Melanoma
- Interventions
- XmAb22841, XmAb23104
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Organ Transplant
- Interventions
- Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Cyclophosphamide, Dexamethasone, Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Larotrectinib (Vitrakvi, BAY2757556)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Orlando, Florida + 7 more
- Conditions
- Vaccination
- Interventions
- IMVAMUNE®
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
- Interventions
- SPY002-072, Placebo
- Drug
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
- Conditions
- Breast Cancer
- Interventions
- Rucaparib, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 8
- States / cities
- Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- DRV/COBI FDC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Multiple Myeloma
- Interventions
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone, Bortezomib
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Westwood, Kansas • Boston, Massachusetts + 1 more
- Conditions
- Pediatric Heart Failure
- Interventions
- LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more